Longitudinal trajectories of basal forebrain volume in normal aging and Alzheimer’s disease

[1]  Christian Gaser,et al.  CAT-A Computational Anatomy Toolbox for the Analysis of Structural MRI Data , 2016 .

[2]  J. Fripp,et al.  Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment , 2022, NeuroImage: Clinical.

[3]  C. Geula,et al.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance , 2021, Journal of neurochemistry.

[4]  Joanne S. Robertson,et al.  Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease , 2021, Journal of Alzheimer's disease reports.

[5]  N. Müller,et al.  Structural MRI of the basal forebrain as predictor of cognitive response to galantamine in healthy older adults: A randomized controlled double‐blinded crossover study , 2020 .

[6]  Vincent Doré,et al.  Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies , 2020, NeuroImage.

[7]  Nicola J. Ray,et al.  New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders , 2020, Current Behavioral Neuroscience Reports.

[8]  Joanne C. Beer,et al.  Longitudinal ComBat: A method for harmonizing longitudinal multi-scanner imaging data☆ , 2020, NeuroImage.

[9]  K. Blennow,et al.  Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease , 2019, Neurology.

[10]  A. Lleó,et al.  Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. , 2019, Cerebral cortex.

[11]  C. Rowe,et al.  Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology , 2019, Alzheimer's & Dementia.

[12]  F. Jessen,et al.  Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD) , 2018, NeuroImage: Clinical.

[13]  Taylor W. Schmitz,et al.  Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections. , 2018, Cell reports.

[14]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[15]  Nicola J. Ray,et al.  Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia , 2018, Current Geriatrics Reports.

[16]  V. Prado,et al.  Cholinergic circuits in cognitive flexibility , 2017, Neuroscience.

[17]  Joanne S. Robertson,et al.  Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging , 2017, Archives of Clinical Neuropsychology.

[18]  Sterling C. Johnson,et al.  Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology , 2016, Nature Communications.

[19]  M. Ananth,et al.  Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline , 2016, Neuron.

[20]  J. L. Cantero,et al.  Volume Loss of the Nucleus Basalis of Meynert is Associated with Atrophy of Innervated Regions in Mild Cognitive Impairment , 2016, Cerebral cortex.

[21]  C. Rowe,et al.  Comparison of MR-less PiB SUVR quantification methods , 2015, Neurobiology of Aging.

[22]  S. Gentleman,et al.  Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease , 2015, Acta Neuropathologica.

[23]  Olivier Salvado,et al.  Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease , 2014, NeuroImage: Clinical.

[24]  Stefan J. Teipel,et al.  Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects , 2014, Alzheimer's & Dementia.

[25]  D. Weaver.  Alzheimer's , 2014, Neurology.

[26]  Stefan Teipel,et al.  Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease , 2014, Neurobiology of Aging.

[27]  H. Heinsen,et al.  Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease , 2013, Neurobiology of Aging.

[28]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[29]  T. Spires-Jones,et al.  Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. , 2013, Journal of neuropathology and experimental neurology.

[30]  H. Heinsen,et al.  Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease , 2012, Biological Psychiatry.

[31]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[32]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[33]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[34]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[35]  Katrin Amunts,et al.  Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain , 2008, NeuroImage.

[36]  John Ashburner,et al.  A fast diffeomorphic image registration algorithm , 2007, NeuroImage.

[37]  H. Möller,et al.  Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. , 2005, Brain : a journal of neurology.

[38]  Reinhard Schliebs,et al.  Basal Forebrain Cholinergic Dysfunction in Alzheimer’s Disease – Interrelationship with β-amyloid, Inflammation and Neurotrophin Signaling , 2005, Neurochemical Research.

[39]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[40]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[41]  M. Mesulam,et al.  From sensation to cognition. , 1998, Brain : a journal of neurology.

[42]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[43]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[44]  A. Levey,et al.  Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey , 1983, The Journal of comparative neurology.

[45]  Jacob Cohen.  Measurement Educational and Psychological Educational and Psychological Measurement Eta-squared and Partial Eta-squared in Fixed Factor Anova Designs Educational and Psychological Measurement Additional Services and Information For , 2022 .

[46]  Taylor W. Schmitz,et al.  Spatial topography of the basal forebrain cholinergic projections: Organization and vulnerability to degeneration. , 2021, Handbook of clinical neurology.

[47]  Stefan Klöppel,et al.  Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. , 2014, Journal of Alzheimer's disease : JAD.

[48]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[49]  J. Wolff,et al.  Morphology of neurons in the rat basal forebrain nuclei: comparison between NADPH-diaphorase histochemistry and immunohistochemistry of glutamic acid decarboxylase, choline acetyltransferase, somatostatin and parvalbumin. , 1991, Journal fur Hirnforschung.